Clinical trials: Mental Test
Pain, Chronic Pain
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care
The purpose of this study is to evaluate the impact of genetic testing on healthcare decisions and patient outcomes for patients suffering from pain, cardiovascular problems, Arthritis, Type II Diabetes, and/or Mental Health…
- Conditions
- Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases
- Trial name
- REVOLUTION (NCT02487888)
- Testing
- Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results
- Where
- 31 sites in United States
- Volunteers
- 100,000 people
- Sponsor
- Proove Bioscience, Inc.
Alzheimer's Disease
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
The purpose of this study is to determine if there is improvement or measurable change in cognition after only one month of treatment with donepezil when using a computerized test battery.
- Trial name
- NCT01024660
- Testing
- Donepezil
- Where
- 18 sites in Canada, Peru and 2 more
- Volunteers
- 155 people
- Sponsor
- AstraZeneca
Mental Health Services
Pilot Test of a Mobile Text Approach to Measurement and Feedback for Wraparound Care Coordination
This SBIR Phase I study will test the acceptability and feasibility of a novel measurement and feedback system tailored to Wraparound service model (WSM) for emotional disorders to produce a feasible, cost-efficient, and scalable…
- Trial name
- SMART-Wrap (NCT05743712)
- Testing
- SMART-Wrap
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- 3-C Institute for Social Development
Alzheimer's Disease
To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden
The purpose of this study is to compare PET measurements of fibrillar amyloid burden using [18F]AZD4694.
- Trial name
- NCT00991419
- Testing
- [18F]AZD4694
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test
This study is designed to test the hypothesis that the Synchronous Neural Interaction™ Test is useful for diagnosing Probable Alzheimer's Disease according to standard criteria.
- Trial name
- NCT00666445
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Orasi Medical, Inc.
Substance Abuse
Substance Treatment and HIV Testing and Referral System
The lack of substance screening and referral in healthcare settings is a significant problem with far-reaching consequences, including excess morbidity, premature mortality, and inflated healthcare costs.
- Trial name
- STaRS (NCT01488630)
- Testing
- STaRS
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Polaris Health Directions
Autism
Testing Conversational Agents as a Digital Companion
There is a need and opportunity to improve the supports, transitions, and life outcomes of people with autism spectrum disorder.
- Trial name
- NCT07533331
- Testing
- self-directed goal coaching
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Friendi.fi Corporation
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP II (NCT06025877)
- Testing
- PrecivityAD2(TM) blood test
- Where
- 9 sites in United States
- Volunteers
- 400 people
- Sponsor
- C2N Diagnostics
Alzheimer Disease
Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease
The purpose of this study is to validate a diagnostic test that combines different blood markers to identify and correctly classify patients with Alzheimer's disease (AD) compared to individuals with behavioural variant…
- Trial name
- RH-VAL (NCT02409030)
- Where
- 16 sites in Belgium, France and 1 more
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Raman Health Technologies, S.L.
Alzheimers Disease
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
The goal of this study is to evaluate whether use of the PrecivityAD2 blood biomarker assay with early result disclosure along with discretionary Precivity-ApoE proteotype testing will shorten the time to Alzheimer's Disease or…
- Trial name
- ADELAIDE (NCT06856681)
- Testing
- PrecivityAD2 - Early Testing, PrecivityAD2 - Delayed Testing
- Sponsor
- C2N Diagnostics
Genetic Health Risks
A Prospective, Monocentric Clinical Study for the Validation of in Vitro Diagnostic Tests Developed by Firalis
Firalis SA and its affiliate Amoneta Diagnostics SAS are developing novel in-vitro-diagnostic (IVD) tests for diverse diagnostic applications for major human diseases, including cardiovascular, and neurodegenerative disorders.
- Trial name
- ApoDiag (NCT06432192)
- Testing
- APO-Easy
- Where
- 2 sites in France
- Volunteers
- 1,474 people, healthy volunteers welcome
- Sponsor
- Firalis SA
Depressive Disorder
Paxil CR Bioequivalence Study Brazil
The study is prospective, open, randomized, crossover in steady state and the volunteers received multiple doses of the drug test and reference (two periods of drug administration).
- Trial name
- NCT01316926
- Testing
- Test formulation, Reference formulation
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depression, Anxiety
Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of…
- Trial name
- NCT02411123
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- AltheaDx
Mild Cognitive Impairment, Metabolic Syndrome
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts…
- Trial name
- NCT03319173
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Obesity, Rhinitis
Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application
The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized…
- Conditions
- Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds
- Trial name
- NCT02758990
- Testing
- Vitamin A, Vitamin B6, Vitamin C
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Verifomics LLC
Autism Spectrum Disorder
Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1
This is a project to be funded by a Fast-Track Small Business Innovative Research to build and test the feasibility of a new software prototype called V-Motive which will facilitate the combination of two proven autism behavioral…
- Trial name
- NCT02500771
- Testing
- ABA therapy enhanced with V-Motive software
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Experiad LLC
Opioid Use Disorder
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
This study is open to people between 18 and 65 years of age with opioid use disorder. Opioid use disorder is also called opioid addiction or opioid dependence.
- Trial name
- NCT06628622
- Testing
- BI 1356225
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Psychotic Disorders
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
This is a study in people between 16 and 30 years of age who have a specific type of mental illness called attenuated psychosis syndrome (APS).
- Trial name
- NCT03230097
- Testing
- BI 409306
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Healthy, Cognitive Function
Safety and Efficacy Study of Qualia Mind on Cognition in a Healthy Population
This is a randomized, double-blind, placebo-controlled, crossover study designed to investigate the safety and efficacy of Qualia Mind on cognition in a healthy adult population between ages of 18 and 75 years.
- Trial name
- NCT04389723
- Testing
- Qualia Mind
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Neurohacker Collective
Alzheimer Disease, Mild Cognitive Impairment
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- REPHRASE (NCT05107882)
- Where
- 7 sites in United States, Canada
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.